ATFB
MCID: FML001
MIFTS: 65

Familial Atrial Fibrillation (ATFB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Mental diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Familial Atrial Fibrillation

MalaCards integrated aliases for Familial Atrial Fibrillation:

Name: Familial Atrial Fibrillation 12 20 43 58 29 6 15 71
Atrial Fibrillation, Familial 20 43 54
Atfb 12 20
Atrial Fibrillation Autosomal Dominant 20
Autosomal Dominant Atrial Fibrillation 20
Atrial Fibrillation, Familial, 1 71
Auricular Fibrillation 43
Atrial Fibrillation 71

Characteristics:

Orphanet epidemiological data:

58
familial atrial fibrillation
Inheritance: Autosomal dominant;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050650
ICD10 via Orphanet 33 I48.9
Orphanet 58 ORPHA334
UMLS 71 C0004238 C1843687 C3468561

Summaries for Familial Atrial Fibrillation

GARD : 20 Familial atrial fibrillation is an inherited heart condition that disrupts the heart's rhythm. It is characterized by erratic electrical activity in the heart's upper chambers (the atria), causing an irregular response in the heart's lower chambers (the ventricles). This causes a fast and irregular heartbeat (arrhythmia). Signs and symptoms may include dizziness, chest pain, palpitations, shortness of breath, or fainting. Affected people also have an increased risk of stroke and sudden death. While complications may occur at any age, some affected people never have associated health problems. Familial atrial fibrillation may be caused by changes (mutations) in any of various genes, some of which have not been identified. It is most often inherited in an autosomal dominant manner, but autosomal recessive inheritance has been reported.

MalaCards based summary : Familial Atrial Fibrillation, also known as atrial fibrillation, familial, is related to atrial fibrillation and cardiac arrhythmia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Familial Atrial Fibrillation is MYL4 (Myosin Light Chain 4), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Ranolazine and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and lung, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An atrial fibrillation that has material basis in autosomal dominant inheritance of the familial atrial fibrillation (ATFB) genes.

MedlinePlus Genetics : 43 Familial atrial fibrillation is an inherited abnormality of the heart's normal rhythm. Atrial fibrillation is characterized by episodes of uncoordinated electrical activity (fibrillation) in the heart's upper chambers (the atria), which cause a fast and irregular heartbeat. If untreated, this abnormal heart rhythm (arrhythmia) can lead to dizziness, chest pain, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, or fainting (syncope). Atrial fibrillation also increases the risk of stroke and sudden death. Complications of atrial fibrillation can occur at any age, although some people with this heart condition never experience any health problems associated with the disorder.

Wikipedia : 74 Familial atrial fibrillation is an autosomal dominant heart condition that causes disruptions in the... more...

Related Diseases for Familial Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Familial Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 31.9 SCN5A SCN4B SCN3B SCN2B PITX2 NUP155
2 cardiac arrhythmia 31.7 SCN5A SCN3B KCNQ1 KCNE2
3 long qt syndrome 31.3 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
4 ventricular fibrillation, paroxysmal familial, 1 31.2 SCN5A NKX2-5 KCNQ1 KCNE2
5 sick sinus syndrome 31.1 SCN5A SCN3B NPPA GJA5
6 sinoatrial node disease 31.0 SCN5A SCN3B NKX2-5 KCNQ1 KCNJ2 GJA5
7 long qt syndrome 10 30.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
8 jervell and lange-nielsen syndrome 1 30.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
9 short qt syndrome 30.8 SCN5A KCNQ1 KCNJ2 KCNE2
10 atrioventricular block 30.8 SCN5A NKX2-5 KCNQ1 KCNE2 GJA5 GATA4
11 familial long qt syndrome 30.8 SCN5A SCN4B KCNQ1 KCNE2
12 syncope 30.8 SCN5A NPPA KCNQ1
13 long qt syndrome 1 30.8 SCN5A SCN4B SCN3B SCN2B NKX2-5 KCNQ1
14 brugada syndrome 30.7 SCN5A SCN4B SCN3B SCN2B NUP155 NKX2-5
15 dilated cardiomyopathy 30.7 SCN5A SCN4B SCN2B NPPA NKX2-5 KCNQ1
16 progressive familial heart block, type ia 30.7 SCN5A GJA5
17 atrial fibrillation, familial, 1 30.7 PITX2 ATFB1
18 wolff-parkinson-white syndrome 30.7 SCN5A NKX2-5 KCNQ1
19 heart disease 30.6 SCN5A PITX2 NPPA NKX2-5 MYL4 KCNQ1
20 aortic valve disease 1 30.6 NKX2-5 KCNJ2 GATA6 GATA5 GATA4
21 patent ductus arteriosus 1 30.5 NKX2-5 GATA6 GATA4
22 atrial fibrillation, familial, 15 11.7
23 brugada syndrome 7 11.7
24 atrial fibrillation, familial, 11 11.2
25 atrial fibrillation, familial, 12 11.2
26 atrial fibrillation, familial, 13 11.2
27 atrial fibrillation, familial, 14 11.2
28 myasthenic syndrome, congenital, 5 10.6 SCN5A KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
29 long qt syndrome 13 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
30 long qt syndrome 5 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
31 long qt syndrome 6 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
32 long qt syndrome 9 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
33 andersen cardiodysrhythmic periodic paralysis 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
34 timothy syndrome 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
35 cardiac arrhythmia, ankyrin-b-related 10.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
36 long qt syndrome 11 10.6 SCN4B KCNQ1 KCNJ2 KCNE2
37 long qt syndrome 3 10.6 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
38 long qt syndrome 2 10.6 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
39 long qt syndrome 12 10.6 SCN5A SCN4B KCNQ1 KCNE2
40 catecholaminergic polymorphic ventricular tachycardia 10.6 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
41 long qt syndrome 14 10.6 SCN5A KCNQ1 KCNJ2
42 atrial standstill 10.6 SCN5A NPPA GJA5
43 intrinsic cardiomyopathy 10.6 SCN5A SCN4B NPPA NKX2-5 KCNQ1 KCNJ2
44 third-degree atrioventricular block 10.6 SCN5A KCNJ2 GJA5
45 mitral valve stenosis 10.6
46 brugada syndrome 4 10.6 SCN5A KCNQ1 KCNJ2
47 congenital myasthenic syndrome 10.6 SCN5A NKX2-5 KCNQ1 KCNJ2 KCNE2 KCNA5
48 ventricular septal defect 10.6 NPPA NKX2-5 GATA6 GATA5 GATA4
49 progressive familial heart block 10.6 SCN5A NKX2-5 KCNQ1 GJA5
50 holt-oram syndrome 10.6 NPPA NKX2-5 GJA5 GATA6 GATA5 GATA4

Comorbidity relations with Familial Atrial Fibrillation via Phenotypic Disease Network (PDN): (show top 50) (show all 169)


Accessory Nerve Disease Acquired Polycythemia
Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Vascular Insufficiency of Intestine
Alcoholic Cardiomyopathy Alcoholic Liver Cirrhosis
Amyloidosis Anemia, Autoimmune Hemolytic
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Aortic Valve Insufficiency Asbestosis
Asthma Atrial Tachyarrhythmia with Short Pr Interval
Atrioventricular Block Bacteremia 2
Basilar Artery Insufficiency Benign Essential Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Bronchiectasis Bronchitis
Bronchopneumonia Candidiasis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Cholangitis Cholecystitis
Chronic Intestinal Vascular Insufficiency Chronic Pulmonary Heart Disease
Chronic Rheumatic Pericarditis Chronic Ulcer of Skin
Colorectal Cancer Conjunctivitis
Constrictive Pericarditis Coronary Artery Aneurysm

Graphical network of the top 20 diseases related to Familial Atrial Fibrillation:



Diseases related to Familial Atrial Fibrillation

Symptoms & Phenotypes for Familial Atrial Fibrillation

UMLS symptoms related to Familial Atrial Fibrillation:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Familial Atrial Fibrillation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
2 homeostasis/metabolism MP:0005376 10 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNE2
3 digestive/alimentary MP:0005381 9.86 GATA4 GATA5 GJA5 KCNE2 KCNJ2 KCNQ1
4 muscle MP:0005369 9.73 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
5 respiratory system MP:0005388 9.17 GATA4 GATA6 GJA5 KCNJ2 NKX2-5 PITX2

Drugs & Therapeutics for Familial Atrial Fibrillation

Drugs for Familial Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
carbamide peroxide Approved Phase 4 124-43-6
4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5 fluindione Approved, Investigational Phase 4 957-56-2
6
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
7
Terazosin Approved Phase 4 63590-64-7 5401
8
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
9
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
10
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
11
Antazoline Approved Phase 4 91-75-8 2200
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
13
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
14
Nifedipine Approved Phase 4 21829-25-4 4485
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
17
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
18
Ezetimibe Approved Phase 4 163222-33-1 150311
19 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
20
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
21
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
24
Acetaminophen Approved Phase 4 103-90-2 1983
25
Pantoprazole Approved Phase 4 102625-70-7 4679
26
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
27
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
28
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
29
Amlodipine Approved Phase 4 88150-42-9 2162
30
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
31
Ticlopidine Approved Phase 4 55142-85-3 5472
32
Atorvastatin Approved Phase 4 134523-00-5 60823
33
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
34
Liraglutide Approved Phase 4 204656-20-2 44147092
35
Methohexital Approved Phase 4 151-83-7 9034
36
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
37
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
38
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
39
Enoxaparin Approved Phase 4 9005-49-6 772
40
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
41
Verapamil Approved Phase 4 52-53-9 2520
42
Ticagrelor Approved Phase 4 274693-27-5 9871419
43
Procainamide Approved Phase 4 51-06-9 4913
44
Digoxin Approved Phase 4 20830-75-5 30322 2724385
45
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
46
Empagliflozin Approved Phase 4 864070-44-0
47
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
48
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
49
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
50
Racepinephrine Approved Phase 4 329-65-7 838

Interventional clinical trials:

(show top 50) (show all 2529)
# Name Status NCT ID Phase Drugs
1 SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial Unknown status NCT02004509 Phase 4 anticoagulant by physician criteria
2 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
3 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
4 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
5 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
6 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
7 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
8 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
9 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
10 A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation Unknown status NCT02389218 Phase 4 sequential drug adjustment (propafenone, sotalol or flecainide)
11 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
12 Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study Unknown status NCT03126214 Phase 4 Anticoagulants
13 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
14 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
15 Cryoballoon Pulmonary Vein Isolation and Associated Esophageal Effects Unknown status NCT02998866 Phase 4
16 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
17 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Unknown status NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
18 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
19 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
20 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
21 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
22 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
23 A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES) Unknown status NCT03536611 Phase 4 dabigatran;warfarin
24 Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial. Unknown status NCT03536806 Phase 4 Saline 0.9%;Canrenone
25 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
26 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
27 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
28 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem
29 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
30 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
31 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
32 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
33 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
34 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
35 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
36 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
37 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
38 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
39 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
40 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
41 Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation Unknown status NCT02673463 Phase 4 Spironolactone;Placebo
42 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
43 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
44 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
45 Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation:a Single-center Randomized Controlled Trial Unknown status NCT04209959 Phase 4 nifekalant
46 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
47 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
48 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
49 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
50 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin

Search NIH Clinical Center for Familial Atrial Fibrillation

Inferred drug relations via UMLS 71 / NDF-RT 51 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Genetic Tests for Familial Atrial Fibrillation

Genetic tests related to Familial Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Familial Atrial Fibrillation 29

Anatomical Context for Familial Atrial Fibrillation

MalaCards organs/tissues related to Familial Atrial Fibrillation:

40
Heart, Endothelial, Lung, Brain, Bone, Spinal Cord, Kidney

Publications for Familial Atrial Fibrillation

Articles related to Familial Atrial Fibrillation:

(show top 50) (show all 108)
# Title Authors PMID Year
1
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 61 54
18929244 2008
2
Cardiac sodium channel mutation in atrial fibrillation. 61 54
18088563 2008
3
Human KCNQ1 S140G mutation is associated with atrioventricular blocks. 61 54
17467630 2007
4
Atrial fibrillation in KCNE1-null mice. 61 54
15947250 2005
5
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. 61 54
15368194 2004
6
KCNQ1 gain-of-function mutation in familial atrial fibrillation. 61 54
12522251 2003
7
Connexin45 (GJC1) loss-of-function mutation contributes to familial atrial fibrillation and conduction disease. 61
33429106 2021
8
ISL1 loss-of-function variation causes familial atrial fibrillation. 61
32771629 2020
9
Clinical profile and outcome of familial versus non-familial atrial fibrillation. 61
32273045 2020
10
Generation of patient-specific induced pluripotent stem cells (ZZUSAHi001-A) derived from a familial atrial fibrillation patient carrying KCNA5 c.775G>A mutation. 61
32721895 2020
11
The Genetic Puzzle of Familial Atrial Fibrillation. 61
32118049 2020
12
Putative role of Brugada syndrome genes in familial atrial fibrillation. 61
31539150 2019
13
Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. 61
31077706 2019
14
Characterization and haplotype study of 6 novel STR markers related to the KCNQ1 gene in heterogeneous cardiovascular disorders in the Iranian population 61
30866607 2019
15
A Novel PITX2c Gain-of-Function Mutation, p.Met207Val, in Patients With Familial Atrial Fibrillation. 61
30558760 2019
16
Proarrhythmia in the p.Met207Val PITX2c-Linked Familial Atrial Fibrillation-Insights From Modeling. 61
31695623 2019
17
Molecular Insights into the Short QT Syndrome. 61
31355049 2018
18
A SHOX2 loss-of-function mutation underlying familial atrial fibrillation. 61
30443179 2018
19
Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. 61
28485191 2017
20
Generation and cardiac subtype-specific differentiation of PITX2-deficient human iPS cell lines for exploring familial atrial fibrillation. 61
28677534 2017
21
A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. 61
27742809 2017
22
Prognosis in Familial Atrial Fibrillation. 61
27866163 2016
23
Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. 61
27866162 2016
24
A novel nonsense mutation in LMNA gene identified by Exome Sequencing in an atrial fibrillation family. 61
27373676 2016
25
Cardiac Delayed Rectifier Potassium Channels in Health and Disease. 61
27261823 2016
26
Clinical Features of Genetic Cardiac Diseases Related to Potassium Channelopathies. 61
27261827 2016
27
A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. 61
27066836 2016
28
Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note. 61
25410959 2015
29
NKX2-6 mutation predisposes to familial atrial fibrillation. 61
25319568 2014
30
TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy. 61
24925317 2014
31
Whole-exome sequencing in familial atrial fibrillation. 61
24727801 2014
32
Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. 61
24648383 2014
33
KCNE2 modulates cardiac L-type Ca(2+) channel. 61
24681347 2014
34
In silico investigation of a KCNQ1 mutation associated with familial atrial fibrillation. 61
24411289 2014
35
Pitx2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. 61
24395921 2014
36
A novel PITX2c loss-of-function mutation associated with familial atrial fibrillation. 61
24333117 2014
37
Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. 61
24006450 2013
38
Prevalence and spectrum of PITX2c mutations associated with familial atrial fibrillation. 61
23611745 2013
39
Characteristics of atrial fibrillation and comorbidities in familial atrial fibrillation. 61
23551519 2013
40
Mutations of the SCN4B-encoded sodium channel β4 subunit in familial atrial fibrillation. 61
23604097 2013
41
A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. 61
23350853 2013
42
A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. 61
23525379 2013
43
A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. 61
23497314 2013
44
Familial atrial fibrillation predicts increased risk of mortality: a study in Danish twins. 61
23255276 2013
45
Polymorphisms but not mutations of the KCNQ1 gene are associated with lone atrial fibrillation in the Chinese Han population. 61
23710137 2013
46
[KCNQ1 mutation in patients with lone atrial fibrillation]. 61
23651960 2013
47
Novel GATA5 loss-of-function mutations underlie familial atrial fibrillation. 61
23295592 2012
48
Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation. 61
22824924 2012
49
Pro-arrhythmogenic effects of the S140G KCNQ1 mutation in human atrial fibrillation - insights from modelling. 61
22508963 2012
50
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. 61
22818067 2012

Variations for Familial Atrial Fibrillation

ClinVar genetic disease variations for Familial Atrial Fibrillation:

6 (show top 50) (show all 70)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYL4 NM_002476.2(MYL4):c.31G>A (p.Glu11Lys) SNV Pathogenic 224067 rs886037778 17:45286819-45286819 17:47209453-47209453
2 KCNQ1OT1 NM_181798.1(KCNQ1):c.1133+3G>A SNV Uncertain significance 304226 rs374767819 11:2683314-2683314 11:2662084-2662084
3 ABCC9 NM_005691.3(ABCC9):c.4316-14T>G SNV Uncertain significance 308032 rs886049168 12:21960427-21960427 12:21807493-21807493
4 KCNQ1-AS1 NM_181798.1(KCNQ1):c.1592C>A (p.Thr531Asn) SNV Uncertain significance 304230 rs377661455 11:2869175-2869175 11:2847945-2847945
5 GJA5 NM_181703.4(GJA5):c.*1211A>G SNV Uncertain significance 292438 rs886045244 1:147229084-147229084 1:147756951-147756951
6 KCNQ1-AS1 NM_181798.1(KCNQ1):c.*26C>A SNV Uncertain significance 304232 rs886048166 11:2869259-2869259 11:2848029-2848029
7 KCNQ1-AS1 NM_181798.1(KCNQ1):c.*887_*889del Deletion Uncertain significance 304264 rs886048175 11:2870119-2870121 11:2848889-2848891
8 KCNQ1-AS1 NM_181798.1(KCNQ1):c.1598C>A (p.Pro533His) SNV Uncertain significance 304231 rs886048165 11:2869181-2869181 11:2847951-2847951
9 KCNQ1-AS1 NM_181798.1(KCNQ1):c.*398C>T SNV Uncertain significance 304246 rs886048170 11:2869631-2869631 11:2848401-2848401
10 KCNQ1-AS1 NM_181798.1(KCNQ1):c.*160C>A SNV Uncertain significance 304234 rs886048167 11:2869393-2869393 11:2848163-2848163
11 KCNQ1-AS1 NM_181798.1(KCNQ1):c.*554T>G SNV Uncertain significance 304252 rs886048172 11:2869787-2869787 11:2848557-2848557
12 KCNQ1 NM_181798.1(KCNQ1):c.870+13C>T SNV Uncertain significance 304220 rs201364493 11:2608935-2608935 11:2587705-2587705
13 KCNQ1 NM_000218.2(KCNQ1):c.66C>T (p.Gly22=) SNV Uncertain significance 304215 rs886048162 11:2466394-2466394 11:2445164-2445164
14 KCNQ1 NM_181798.1(KCNQ1):c.269C>T (p.Ser90Phe) SNV Uncertain significance 304217 rs886048163 11:2592600-2592600 11:2571370-2571370
15 KCNQ1 NM_181798.1(KCNQ1):c.974G>A (p.Arg325Gln) SNV Uncertain significance 67030 rs145229963 11:2610046-2610046 11:2588816-2588816
16 KCNQ1 NM_181798.1(KCNQ1):c.400-6G>T SNV Uncertain significance 304218 rs886048164 11:2594070-2594070 11:2572840-2572840
17 KCNE2 NM_172201.1(KCNE2):c.-121C>T SNV Uncertain significance 339713 rs188625398 21:35736342-35736342 21:34364043-34364043
18 KCNQ1 NM_181798.1(KCNQ1):c.808C>T (p.Arg270Trp) SNV Uncertain significance 52970 rs199472776 11:2608860-2608860 11:2587630-2587630
19 ABCC9 NM_005691.3(ABCC9):c.2238-16del Deletion Uncertain significance 308036 rs886049170 12:22016004-22016004 12:21863070-21863070
20 ABCC9 NM_005691.3(ABCC9):c.1165-7_1165-6del Deletion Uncertain significance 308043 rs35857705 12:22063252-22063253 12:21910318-21910319
21 KCNQ1-AS1 NM_181798.1(KCNQ1):c.*292C>A SNV Uncertain significance 304240 rs886048169 11:2869525-2869525 11:2848295-2848295
22 KCNQ1 NM_000218.2(KCNQ1):c.29C>A (p.Ala10Asp) SNV Uncertain significance 304214 rs886048161 11:2466357-2466357 11:2445127-2445127
23 GJA5 NM_181703.4(GJA5):c.*1259C>T SNV Uncertain significance 292437 rs886045243 1:147229036-147229036 1:147756903-147756903
24 GJA5 NM_005266.6(GJA5):c.-67G>A SNV Uncertain significance 292457 rs36214923 1:147245389-147245389 1:147773285-147773285
25 KCNQ1-AS1 NM_181798.1(KCNQ1):c.*897G>T SNV Uncertain significance 304266 rs561861522 11:2870130-2870130 11:2848900-2848900
26 ABCC9 NM_005691.3(ABCC9):c.1165-4del Deletion Uncertain significance 308042 rs886049172 12:22063250-22063250 12:21910316-21910316
27 ABCC9 NM_005691.3(ABCC9):c.1165-19dup Duplication Uncertain significance 45385 rs35857705 12:22063251-22063252 12:21910317-21910318
28 LAMA4 NM_001105206.3(LAMA4):c.3742A>G (p.Ile1248Val) SNV Uncertain significance 488160 rs547323858 6:112454047-112454047 6:112132845-112132845
29 KCNJ2 NM_000891.2(KCNJ2):c.*2776del Deletion Uncertain significance 324885 rs886053343 17:68175240-68175240 17:70179099-70179099
30 KCNJ2 NM_000891.2(KCNJ2):c.*1704_*1705dupCT Microsatellite Uncertain significance 324864 rs1555604187 17:68174165-68174166 17:70178024-70178025
31 KCNJ2 NM_000891.2(KCNJ2):c.*2775dup Duplication Uncertain significance 324879 rs35656864 17:68175205-68175206 17:70179064-70179065
32 KCNJ2 NM_000891.2(KCNJ2):c.-88C>T SNV Uncertain significance 324828 rs886053322 17:68171093-68171093 17:70174952-70174952
33 KCNJ2 NM_000891.2(KCNJ2):c.*1719_*1721dup Duplication Uncertain significance 324867 rs35753731 17:68174168-68174169 17:70178027-70178028
34 KCNJ2 NM_000891.2(KCNJ2):c.*2774_*2775del Deletion Uncertain significance 324880 rs35656864 17:68175206-68175207 17:70179065-70179066
35 KCNJ2 NM_000891.2(KCNJ2):c.*1721dup Duplication Uncertain significance 324865 rs35753731 17:68174168-68174169 17:70178027-70178028
36 KCNJ2 NM_000891.2(KCNJ2):c.*324del Deletion Uncertain significance 324839 rs570173316 17:68172786-68172786 17:70176645-70176645
37 KCNJ2 NM_000891.2(KCNJ2):c.*3391_*3392dup Duplication Uncertain significance 324894 rs552636156 17:68175852-68175853 17:70179711-70179712
38 KCNJ2 NM_000891.2(KCNJ2):c.*2875_*2876del Deletion Uncertain significance 324887 rs561353262 17:68175339-68175340 17:70179198-70179199
39 KCNJ2 NM_000891.2(KCNJ2):c.*2771_*2775del Deletion Uncertain significance 324882 rs35656864 17:68175206-68175210 17:70179065-70179069
40 KCNJ2 NM_000891.2(KCNJ2):c.*2772_*2775del Deletion Uncertain significance 324881 rs35656864 17:68175206-68175209 17:70179065-70179068
41 KCNJ2 NM_000891.2(KCNJ2):c.*1702dup Duplication Uncertain significance 324863 rs886053334 17:68174165-68174166 17:70178024-70178025
42 KCNJ2 NM_000891.2(KCNJ2):c.*1702_*1704dup Duplication Uncertain significance 324862 rs1555604193 17:68174165-68174166 17:70178024-70178025
43 KCNJ2 NM_000891.2(KCNJ2):c.*2770_*2775del Deletion Uncertain significance 324883 rs35656864 17:68175206-68175211 17:70179065-70179070
44 KCNJ2 NM_000891.2(KCNJ2):c.-162delinsTCAGAGTAGT Indel Uncertain significance 324827 rs376713253 17:68171019-68171019 17:70174878-70174878
45 KCNJ2 NM_000891.2(KCNJ2):c.*1128dup Duplication Uncertain significance 324851 rs777658732 17:68173591-68173592 17:70177450-70177451
46 KCNJ2 NM_000891.2(KCNJ2):c.*1720_*1721dup Duplication Uncertain significance 324866 rs35753731 17:68174168-68174169 17:70178027-70178028
47 KCNJ2 NM_000891.2(KCNJ2):c.1259C>T (p.Pro420Leu) SNV Uncertain significance 264482 rs749707062 17:68172439-68172439 17:70176298-70176298
48 KCNJ2 NM_000891.2(KCNJ2):c.*3463del Deletion Uncertain significance 324895 rs3841509 17:68175918-68175918 17:70179777-70179777
49 KCNA5 NM_002234.3(KCNA5):c.*800G>A SNV Likely benign 369020 rs4625555 12:5155955-5155955 12:5046789-5046789
50 KCNQ1OT1 NM_181798.1(KCNQ1):c.1012+21538C>T SNV Likely benign 304222 rs72850203 11:2631622-2631622 11:2610392-2610392

Expression for Familial Atrial Fibrillation

Search GEO for disease gene expression data for Familial Atrial Fibrillation.

Pathways for Familial Atrial Fibrillation

Pathways related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.42 SCN5A SCN4B SCN3B SCN2B NPPA NKX2-5
2
Show member pathways
12.38 SCN5A SCN4B NPPA MYL4 KCNQ1 GATA4
3 12.17 KCNQ1 KCNJ2 KCNE2 KCNA5
4 11.99 SCN5A SCN4B SCN3B KCNQ1
5
Show member pathways
11.85 SCN5A SCN4B SCN3B SCN2B
6
Show member pathways
11.51 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNE2
7 11.4 SCN5A NKX2-5 GATA4
8 11.34 MYL4 GATA6 GATA4
9 11.33 PITX2 NKX2-5 GATA6 GATA4
10 11.03 SCN5A SCN4B SCN3B SCN2B
11 11.02 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
12 10.95 NPPA NKX2-5 GATA4
13 10.8 KCNQ1 KCNJ2
14 10.28 NPPA NKX2-5 GATA4

GO Terms for Familial Atrial Fibrillation

Cellular components related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated potassium channel complex GO:0008076 9.46 KCNQ1 KCNJ2 KCNE2 KCNA5
2 Z disc GO:0030018 9.43 SCN5A SCN3B KCNA5
3 voltage-gated sodium channel complex GO:0001518 9.26 SCN5A SCN4B SCN3B SCN2B
4 intercalated disc GO:0014704 9.02 SCN5A SCN4B KCNJ2 KCNA5 GJA5

Biological processes related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.15 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
2 potassium ion transport GO:0006813 9.97 KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
3 potassium ion transmembrane transport GO:0071805 9.93 KCNQ1 KCNJ2 KCNE2 KCNA5
4 sodium ion transport GO:0006814 9.93 SCN5A SCN4B SCN3B SCN2B
5 sodium ion transmembrane transport GO:0035725 9.92 SCN5A SCN4B SCN3B SCN2B
6 regulation of ion transmembrane transport GO:0034765 9.92 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
7 cardiac conduction GO:0061337 9.85 SCN5A SCN3B KCNQ1 KCNJ2 KCNE2
8 cell fate commitment GO:0045165 9.83 GATA6 GATA5 GATA4
9 aortic valve morphogenesis GO:0003180 9.83 NPPA NKX2-5 GATA5 GATA4
10 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.81 SCN5A SCN4B KCNQ1 KCNE2
11 ventricular cardiac muscle cell action potential GO:0086005 9.8 SCN5A SCN3B KCNQ1 KCNE2
12 positive regulation of heart rate GO:0010460 9.79 SCN3B NPPA KCNQ1
13 cardiac muscle cell differentiation GO:0055007 9.79 NKX2-5 GATA6 GATA4
14 regulation of sodium ion transmembrane transporter activity GO:2000649 9.78 SCN4B SCN3B SCN2B
15 positive regulation of sodium ion transport GO:0010765 9.78 SCN5A SCN4B SCN3B NKX2-5
16 potassium ion export across plasma membrane GO:0097623 9.77 KCNQ1 KCNE2 KCNA5
17 regulation of cardiac muscle cell contraction GO:0086004 9.77 SCN5A KCNJ2 GATA4
18 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.77 SCN5A SCN4B SCN3B SCN2B KCNJ2
19 regulation of membrane repolarization GO:0060306 9.76 KCNQ1 KCNJ2 KCNE2
20 membrane repolarization during action potential GO:0086011 9.74 KCNQ1 KCNJ2 KCNE2
21 intestinal epithelial cell differentiation GO:0060575 9.73 GATA6 GATA5 GATA4
22 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.73 SCN5A SCN3B SCN2B GJA5
23 positive regulation of cardioblast differentiation GO:0051891 9.71 NKX2-5 GATA6 GATA4
24 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.71 SCN5A NPPA KCNQ1 KCNA5
25 cardiac muscle tissue development GO:0048738 9.7 GATA6 GATA5
26 cardiac muscle contraction GO:0060048 9.7 SCN5A SCN4B SCN3B SCN2B NKX2-5 MYL4
27